"Evaluating Immuno-Oncology Treatment With PK/PD Modelling "

World Preclinical Congress, Lisbon, 16 Nov 2017

12. Evaluating Immuno-Oncology Treatment With PK/PD Modelling (3-hour short course). World Preclinical Congress Europe (Cambridge Innovation Institute), Sheraton Lisboa Hotel & Spa, Lisbon (11/2017) PDF


• Introduce how translational PK/PD modelling for chemotherapy and cell-directed targeted therapy can be used to relate preclinical data with clinical response

• The basics of PK/PD modelling that are relevant to evaluating novel immuno-oncology treatments

• Learn about dose selection, estimation of therapeutic window, and translational sciences based on PK/PD modelling

Lecture 1. Translational modelling for cell-directed cancer therapies: the successful case studies 

The lecture will provide a historical perspective for translational modelling that has been developed for chemotherapies and cancer cell-directed targeted therapies. It will discuss the following topics: 

• How do we define the quantitative relationship between preclinical efficacy and clinical activity for this type of treatment? 

• What does compelling preclinical evidence entail? 

• Is it possible to set minimum preclinical efficacy criteria to qualify a novel treatment for clinical success?


Group exercise 1 

• Limitations of the approach/conclusions 

• How shall this translational modelling framework be used in practice to best support drug projects? 

• Where does it add value? 

• Which ideas can be borrowed to support immuno-oncology projects? 1


Lecture 2. The basics of immuno-oncology modelling

This lecture will focus on the basics of immuno-oncology modelling, including: 

• Target-mediated drug disposition (TMDD): translating preclinical antibody PK into the clinics 

• Target engagement modelling: a MABEL example

Case study: Predict human PK using in vitro and monkey data with Target Mediated Drug Disposition (TMDD) modelling

Case study: First-in-human (FIH) dose finding for bispecific immunomodulatory P-Cadherin LP-DART with mechanistic PK/PD modelling MABEL approach


Group exercise 2 

• What are the main gaps from target engagement to disease modulation to (preclinical and clinical) outcome? 

• How to fill in these gaps in practice to enable robust clinical translation of preclinical results? 

Company registration no. 09698685

Registered in England and Wales.

14 Tytherington Park Road, Macclesfield, Cheshire, UK  SK10 2EL 

Beyond Consulting Ltd

+44-7853 073 731